about
ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndromeENDOCRINE TUMOURS: The genomics of adrenocortical tumorsARMC5 Mutations in a Large Cohort of Primary Macronodular Adrenal Hyperplasia: Clinical and Functional ConsequencesMacronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation.Loss-of-function mutations in the CABLES1 gene are a novel cause of Cushing's diseaseIGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma.Primary Aldosteronism and ARMC5 Variants.Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome.SNP arrays in heterogeneous tissue: highly accurate collection of both germline and somatic genetic information from unpaired single tumor samples.Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments.The 'omics' of adrenocortical tumours for personalized medicine.Biological and radiological exploration and management of non-functioning pituitary adenoma.Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.WNT/β-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production.Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation.Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1A) inhibits SMAD3 expression and TGF beta-stimulated apoptosis in adrenocortical cells.DNA Methylation Is an Independent Prognostic Marker of Survival in Adrenocortical Cancer.Serum RARRES2 Is a Prognostic Marker in Patients With Adrenocortical Carcinoma.Systematic analysis of G protein-coupled receptor gene expression in adrenocorticotropin-independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing's syndrome.Calling Chromosome Alterations, DNA Methylation Statuses, and Mutations in Tumors by Simple Targeted Next-Generation Sequencing: A Solution for Transferring Integrated Pangenomic Studies into Routine Practice?Molecular screening for a personalized treatment approach in advanced adrenocortical cancer.Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients.[Familial aspect of primary hyperaldosteronism: analysis of families compatible with primary hyperaldosteronism type 2].Detection and monitoring of circulating tumor DNA in adrenocortical carcinoma.Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson's tumor.Adrenalectomy for incidentaloma: lessons learned from a single-centre series of 274 patients.Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma.Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas.Integrated genomic characterization of adrenocortical carcinoma.Central vestibular networks in the guinea-pig: functional characterization in the isolated whole brain in vitro.Systematic Analysis of G Protein-Coupled Receptor Gene Expression in Adrenocorticotropin-Independent Macronodular Adrenocortical Hyperplasia Identifies Novel Targets for Pharmacological Control of Adrenal Cushing’s Syndrome.Efficacy of endoscopic endonasal transsphenoidal surgery for Cushing's disease in 230 patients with positive and negative MRI.Inter- and intra-observer variability in detection and progression assessment with MRI of microadenoma in Cushing's disease patients followed up after bilateral adrenalectomy.From benign adrenal incidentaloma to adrenocortical carcinoma: an exceptional random event.Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas.Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.Identification of gene expression profiles associated with cortisol secretion in adrenocortical adenomas.One single signaling pathway for so many different biological functions: lessons from the cyclic adenosine monophosphate/protein kinase A pathway-related diseases.High Diagnostic and Prognostic Value of Steroidogenic Factor-1 Expression in Adrenal Tumors.High Diagnostic and Prognostic Value of Steroidogenic Factor-1 Expression in Adrenal Tumors
P50
Q24310286-6553DAAB-70DB-4827-B392-24623E86EE86Q26770421-75CBD5A6-B9C3-4EE9-B59D-E373679DAB2EQ33570265-5727A26A-FF01-4EA5-A750-8816D9BFD678Q33682397-24D0321E-0B44-4EB0-9946-0140F15087D9Q33904619-3B3A88E9-DE1B-4329-8CD4-FE9025AED790Q33999643-8C64B6CF-5B54-40CC-A4F4-33EA006160A8Q35680827-67E50D14-BB6C-43E2-B73B-C57CD422CED0Q36503929-7F7AED32-ED86-41E1-A232-AD6128A92EE5Q36718929-A1381C2F-9369-420D-A9BA-99BBBA1FEFDEQ37826288-447E944A-987E-4517-97E1-0FD9CE55049AQ38184819-03B9E31A-7666-4495-94CB-DA7884BBFBD4Q38540037-F6740AE6-E8D1-443B-B8BB-C1CF6367BCBDQ38825813-A46923CA-5BB9-47BA-A1D4-83A1E98D183BQ39088795-AAF25F31-7869-4E75-9780-1AB3FD774C18Q39623012-F396BB02-52DF-46D1-8839-77B0A50B5878Q39802037-C1E5A577-1299-4C60-8C51-E5C3B852E944Q40425821-6224F454-791F-4FA3-8430-EEDE115D2B49Q41010316-6E05E56C-9657-458D-8A65-F9E111B6A3B8Q42474931-403C6CE1-AFA9-48FA-85BA-32A0D79D0DB6Q42697617-53E24312-72F6-44EC-BECE-82C80C5F5E25Q43735840-16FAC539-447E-4E28-95F8-5335AE3ED5CEQ44445302-168D9EE6-FB5B-42D6-93B0-BE5048557AFDQ46575657-2BCDEA20-753F-4556-BCD1-2E1B27E75749Q47199196-51023D30-5CE7-4907-8007-CB5E93C8505AQ47690666-A04F9008-3EE3-44DE-8593-01741A2881ADQ47706209-5D0324C3-F653-4350-B1A2-CED32B38FAFBQ47801407-767DE213-CC0C-4EF5-9AA0-E20E4FFCCD37Q48305502-234E6D0A-71B6-4ED4-ACCD-BE688C79564FQ48315182-125ECD1F-6740-4516-8458-A3AC79475A12Q48626931-015790C2-D86E-49A1-8BAD-08655D543A20Q49602816-C9AD60DF-A4AF-4F95-8785-D5160016FBCFQ50851489-EBFED104-C269-4FE2-B6AC-A705A0707A01Q53037077-AA65B635-4E4B-4031-82C1-C3197AA07936Q53397166-5EE95DEA-7D26-43FD-8367-3A389F392DA9Q54389825-20704668-B3B1-42D2-BF60-2296F5B9271CQ54405863-C1FCB883-4B67-41E2-8366-4152AE12F4CEQ54440769-8E406264-1003-4ECB-B781-618383A8C43BQ54466824-709242B1-A3E1-4EF5-A5FA-E03D5A1B4ED6Q55351648-94EA3F3C-096F-405E-A08C-55CDE5E5D22DQ56964345-554E8BEF-4A97-4260-8DF0-57209D44A074
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Guillaume Assié
@ast
Guillaume Assié
@en
Guillaume Assié
@es
Guillaume Assié
@nl
type
label
Guillaume Assié
@ast
Guillaume Assié
@en
Guillaume Assié
@es
Guillaume Assié
@nl
prefLabel
Guillaume Assié
@ast
Guillaume Assié
@en
Guillaume Assié
@es
Guillaume Assié
@nl
P214
P106
P214
P31
P496
0000-0001-9590-0906
P735
P7859
viaf-215237870